Literature DB >> 6953982

Causes of initial remission induction failure in acute myelogenous leukemia.

E H Estey, M J Keating, K B McCredie, G P Bodey, E J Freireich.   

Abstract

One-hundred and sixty-one of 378 previously untreated patients with acute myelogenous leukemia (AML) failed to enter complete remission with a combination of anthracycline, cytosine arabinoside, vincristine, and prednisone between 1973 and 1979. Thirty-six of the failing patients (22%) were considered chemotherapy failures. As in the past, the remainder failed largely because of death from infection. However, despite the routine use of prophylactic platelet transfusions, hemorrhage was a major cause of death in 33%. Thirty-seven percent of the fatal infections were due to fungi and the incidence of fungal infection was as high during the second week of treatment as later. Age greater than 50 yr predisposed to fatal infection but not chemotherapy failure, while the presence of an antecedent hematologic disorder increased the risk of both fatal fungal infection and resistance to chemotherapy. Patients with an initial white blood cell count of greater than or equal to 25000/microliter were more likely to die of hemorrhage at all times during treatment. Improvement in supportive care remains crucial if improved complete rates are to be forthcoming in previously untreated patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953982

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  The critical role of iron in some clinical infections.

Authors:  J J Bullen; C G Ward; H J Rogers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

Review 2.  Minimising the side effects of cancer chemotherapy in senior patients.

Authors:  T Kinzel; V Feleppa
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 3.  Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia.

Authors:  S Bolam; T Hamblin
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

4.  Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.

Authors:  Sonja Burgstaller; Petra Wiesinger; Reinhard Stauder
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

5.  Fatal legionellosis in patients with malignant hematologic diseases.

Authors:  D Schürmann; B Ruf; F Pfannkuch; I Horbach; H D Pohle
Journal:  Blut       Date:  1988-01

Review 6.  Chronic systemic candidiasis.

Authors:  G P Bodey; E J Anaissie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

7.  Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.

Authors:  Naval Daver; Hagop Kantarjian; Guido Marcucci; Sherry Pierce; Mark Brandt; Courtney Dinardo; Naveen Pemmaraju; Guillermo Garcia-Manero; Susan O'Brien; Alessandra Ferrajoli; Srdan Verstovsek; Uday Popat; Chitra Hosing; Paolo Anderlini; Gautam Borthakur; Tapan Kadia; Jorge Cortes; Farhad Ravandi
Journal:  Br J Haematol       Date:  2014-10-14       Impact factor: 6.998

8.  Prognosis of infections in elderly patients with haematological diseases.

Authors:  F Rossini
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

Review 9.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 10.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.